Caprelsa (vandetanib)

News alerts, weekly reports and conference planners

Company:

Sanofi

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	vandetanib Sensitive: A2 - Guideline vandetanib Sensitive : A2	vandetanib Sensitive: A2 - Guideline vandetanib Sensitive : A2
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3
RET overexpression	Estrogen Receptor Positive Breast Cancer	RET overexpression	Estrogen Receptor Positive Breast Cancer	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	everolimus + vandetanib Sensitive: C3 – Early Trials everolimus + vandetanib Sensitive : C3	everolimus + vandetanib Sensitive: C3 – Early Trials everolimus + vandetanib Sensitive : C3
AKT2 amplification	Lung Adenocarcinoma	AKT2 amplification	Lung Adenocarcinoma	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4
NF1 mutation	Thyroid Gland Medullary Carcinoma	NF1 mutation	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4
RET M918T + ATM L804fs4 + ATM S978fs12	Thyroid Gland Medullary Carcinoma	RET M918T + ATM L804fs4 + ATM S978fs12	Thyroid Gland Medullary Carcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4
ATM S978fs*12	Thyroid Gland Medullary Carcinoma	ATM S978fs*12	Thyroid Gland Medullary Carcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4
ATM L804fs*4	Thyroid Gland Medullary Carcinoma	ATM L804fs*4	Thyroid Gland Medullary Carcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4
ATM S978fs*12	Thyroid Gland Medullary Carcinoma	ATM S978fs*12	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4
KIF5B-RET fusion	Lung Adenocarcinoma	KIF5B-RET fusion	Lung Adenocarcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4
PIK3CA H1047R	Salivary Gland Cancer	PIK3CA H1047R	Salivary Gland Cancer	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4
KDR Q472H + KIT M541L	Sarcoma	KDR Q472H + KIT M541L	Sarcoma	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4
PIK3CA Q546K	Thyroid Gland Carcinoma	PIK3CA Q546K	Thyroid Gland Carcinoma	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4
EGFR expression	Squamous Cell Carcinoma of Head and Neck	EGFR expression	Squamous Cell Carcinoma of Head and Neck	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
KIF5B-RET fusion	Lung Adenocarcinoma	KIF5B-RET fusion	Lung Adenocarcinoma	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
RET overexpression	Breast Cancer	RET overexpression	Breast Cancer	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
EGFR overexpression	Breast Cancer	EGFR overexpression	Breast Cancer	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
BCR-ABL1 V299L	Acute Lymphocytic Leukemia	BCR-ABL1 V299L	Acute Lymphocytic Leukemia	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
KIAA1217-RET fusion	Lung Adenocarcinoma	KIAA1217-RET fusion	Lung Adenocarcinoma	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
ACVR1 mutation	Glioma	ACVR1 mutation	Glioma	everolimus + vandetanib Sensitive: D – Preclinical everolimus + vandetanib Sensitive : D	everolimus + vandetanib Sensitive: D – Preclinical everolimus + vandetanib Sensitive : D
MPZL3 overexpression	Breast Cancer	MPZL3 overexpression	Breast Cancer	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D

Caprelsa (vandetanib)

Associations
(26)

Associations
(26)

Caprelsa (vandetanib)

Associations(26)

Associations(26)

Associations
(26)

Associations
(26)